Medicus Pharma prices $3.0 million offering as Nasdaq deadline nears
The company is selling shares at $1.72 and pre-funded warrants at $1.7199 while running concurrent deals aimed at fixing a shareholders' equity shortfall before a November 16 Nasdaq compliance deadline.
Medicus Pharma Ltd. priced a public offering of 97,973 common shares and pre-funded warrants to purchase up to 1,646,213 common shares. The offering price is $1.72 per common share, which was the closing price of the company's common shares on Nasdaq on November 12, 2026, and $1.7199 per pre-funded warrant, which is equal to the offering price per common share minus $0.0001, the exercise price per share of each pre-funded warrant.1 The aggregate gross proceeds from this offering will be approximately $3.0 million, before deducting estimated offering expenses and excluding any proceeds from the exercise of the pre-funded warrants.1
Alongside the offering, Medicus arranged two concurrent transactions. The company is selling 726,730 common shares in a private placement to a limited number of accredited investors, including members of management and directors such as Dr. Raza Bokhari, its Executive Chairman and CEO, for aggregate gross proceeds of approximately $1.25 million, and it issued 105,000 non-convertible, non-voting preferred shares to Streeterville Capital, LLC in exchange for $10.5 million in principal amount of outstanding indebtedness.1 The public offering is conditioned upon the consummation of the concurrent private placement.1
The timing relates to Nasdaq listing requirements. On May 20, 2026, Medicus received notice from Nasdaq that its market value of listed securities had been below $35 million for 30 consecutive business days, putting it out of compliance with Listing Rule 5550(b)(2).1 The company was given 180 days, until November 16, 2026, to regain compliance or satisfy an alternative standard, including maintaining shareholders' equity of at least $2.5 million.1 As of September 30, 2026, Medicus had a total shareholders' deficit of approximately $10.5 million.1 The company said it believes the offering, the concurrent transactions, and at-the-market sales since September 30, 2026 will cause it to satisfy the Equity Standard, though it cautioned there is no assurance Nasdaq will make that determination or that compliance will be maintained.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.